A phase I study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced, HER2-positive (HER2+) breast cancer

被引：0
|
作者：
Munster, Pamela N.
Miller, Kathy
Krop, Ian E.
Dhindsa, Navreet
Reynolds, Joe
Geretti, Elena
Niyikiza, Clet
Nielsen, Ulrik
Hendriks, Bart
Wickham, Thomas J.
Moyo, Victor M.
LoRusso, Patricia
机构：
[1] Univ Calif San Francisco, San Francisco Helen Diller Family Comprehens Canc, San Francisco, CA 94143 USA
[2] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Merrimack Pharmaceut, Cambridge, MA USA
[5] Karmanos Canc Inst, Detroit, MI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS663
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Quantitative evaluation of HER2-mediated cellular uptake of the HER2-targeted antibody-liposomal doxorubicin conjugate MM-302 suggests potential for treating HER2-intermediate tumors
    Geretti, E.
    Espelin, C.
    Adiwijaya, B.
    Dumont, N.
    Coma, S.
    Koncki, Z.
    Garcia, G.
    Bloom, T.
    Rimkunas, V.
    Reynolds, J.
    Campbell, K.
    Moyo, V.
    Molnar, I.
    Lorusso, P.
    Miller, K.
    Ma, C.
    Krop, I. E.
    Munster, P.
    Wickham, T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [22] Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)
    Geretti, Elena
    Leonard, Shannon Curtis
    Dumont, Nancy
    Lee, Helen
    Zheng, Jinzi
    De Souza, Raquel
    Gaddy, Daniel F.
    Espelin, Christopher W.
    Jaffray, David A.
    Moyo, Victor
    Nielsen, Ulrik B.
    Wickham, Thomas J.
    Hendriks, Bart S.
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (09) : 2060 - 2071
  • [23] HER2-targeted Therapeutic Strategies for HER2-positive Metastatic Breast Cancers
    Fujii, Teruhiko
    Miwa, Keisuke
    Ushijima, Tomoyuki
    Matsunaga, Mototsugu
    Fukahori, Masaru
    Yuge, Kotaro
    Toh, Uhi
    Iwakuma, Nobutaka
    Takahashi, Ryuji
    Takahashi, Hiroki
    Takenaka, Miki
    Mishima, Mai
    Akagi, Yoshito
    Kage, Masayoshi
    Nakagawa, Shino
    CURRENT CANCER THERAPY REVIEWS, 2014, 10 (03) : 225 - 233
  • [24] A Phase 2 study of poziotinib in patients with HER2-positive metastatic breast cancer heavily pre-treated with HER2-targeted therapy
    Brufsky, Adam
    Zulfiqar, Malik
    Peguero, Julio
    Lathrop, Kate
    Bhat, Gajanan
    Lebel, Francois
    CANCER RESEARCH, 2021, 81 (04)
  • [25] Molecular Basis of HER2-Targeted Therapy for HER2-Positive Colorectal Cancer
    Yoshikawa, Ayumu
    Nakamura, Yoshiaki
    CANCERS, 2023, 15 (01)
  • [26] Delayed initiation of HER2-targeted therapy (HER2Tx) is associated with a higher risk of relapse for early stage (ES) HER2-positive (HER2+) breast cancer (BrCa)
    Gullo, G.
    Bose, R.
    Walsh, N.
    Maltese, M.
    Fennelly, D.
    Walshe, J.
    Ballot, J.
    Crown, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [27] Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
    Griguolo, Gaia
    Pascual, Tomas
    Dieci, Maria Vittoria
    Guarneri, Valentina
    Prat, Aleix
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [28] HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future
    Xu, Luying
    Xie, Yuxin
    Gou, Qiheng
    Cai, Rui
    Bao, Rong
    Huang, Yucheng
    Tang, Ruisi
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [29] Combination of HER2-targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer
    Matusz-Fisher, Ashley
    Tan, Antoinette R.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (03) : 385 - 395
  • [30] A phase Ib study of lapatinib plus pegylated liposomal doxorubicin in patients with advanced HER2-positive breast cancer.
    Rocca, Andrea
    Cecconetto, Lorenzo
    Passardi, Alessandro
    Melegari, Elisabetta
    Andreis, Daniele
    Monti, Manuela
    Maltoni, Roberta
    Sarti, Samanta
    Pietri, Elisabetta
    Schirone, Alessio
    Fedeli, Anna
    Donati, Caterina
    Nanni, Oriana
    Amadori, Dino
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345